China SXT Pharmaceuticals (SXTC) Accumulated Depreciation & Amortization (2018 - 2025)
China SXT Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $2.4 million for Q1 2025.
- For Q1 2025, Accumulated Depreciation & Amortization changed 0.09% year-over-year to $2.4 million; the TTM value through Mar 2025 reached $2.4 million, changed 0.09%, while the annual FY2025 figure was $2.4 million, 0.09% changed from the prior year.
- Accumulated Depreciation & Amortization for Q1 2025 was $2.4 million at China SXT Pharmaceuticals, roughly flat from $2.4 million in the prior quarter.
- Over five years, Accumulated Depreciation & Amortization peaked at $2.4 million in Q1 2025 and troughed at $1.5 million in Q1 2021.
- A 5-year average of $2.0 million and a median of $1.9 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Biggest five-year swings in Accumulated Depreciation & Amortization: soared 42.15% in 2021 and later rose 0.09% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $1.5 million in 2021, then increased by 25.0% to $1.8 million in 2022, then rose by 5.58% to $1.9 million in 2023, then grew by 25.97% to $2.4 million in 2024, then rose by 0.09% to $2.4 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for SXTC at $2.4 million in Q1 2025, $2.4 million in Q1 2024, and $1.9 million in Q1 2023.